Copeptin Kinetics in Critically Ill Patients With Posterior Reversible Encephalopathy Syndrome (XPRESSE)

NCT04950270 COMPLETED

XPRESSE is a multicenter observational prospective biomarker study in which critically ill patients with MRI-based PRES diagnosis will have copeptin kinetics from a daily blood sample for 6 days and a 3-month follow-up. This study aims to investigate the relationship between copeptin and PRES in order to establish the optimal therapeutic time window for vaptan treatment against PRES. Data collection using an electronic case report form will include demographic data, medical history and data related to PRES: onset modalities and date of symptoms control, radiological features of PRES, biological investigations, results of etiological investigations and therapeutic management (e.g., anticonvulsants, antihypertensive drugs, supportive treatments). Outcomes will include modified Rankin scale score and Glasgow Outcome Scale score at ICU discharge, 3-month modified Rankin Scale score and 3-month mortality.

Details

Lead sponsor	University Hospital, Tours
Status	COMPLETED
Enrolment	24
Start date	Sat Jun 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Feb 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Posterior Reversible Encephalopathy Syndrome

Interventions

• Blood copeptin monitoring
• phone interview

Countries

France